Ultrasound clues may forecast Flare-Ups in blood vessel disease
NCT ID NCT06894602
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether ultrasound scans of the temporal and axillary arteries can help predict relapses in people with giant cell arteritis, a disease that causes inflamed blood vessels. Researchers will follow 100 patients to see if certain ultrasound findings are linked to future flare-ups. The goal is to improve how doctors monitor the disease and decide on treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict relapses in giant cell arteritis patients using ultrasound, leading to better monitoring and treatment adjustments.
- What could go wrong
- This is an observational study with only 100 participants, so results may not apply to all patients. It does not test a new treatment, so it won't directly change therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients with giant cell arteritis at disease diagnosis
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Major patient * Patients meeting ACR 2022 criteria for giant cell arteritis. * No opposition expressed Exclusion Criteria: * Patients unable to understand the protocol, under guardianship or curatorship. * Patients not affiliated to the French Social Security system.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Giant cell arteritis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Ch Quimper
RECRUITINGQuimper, 29107, France
-
Chu Brest
RECRUITINGBrest, 29200, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- New tool could predict who will suffer from steroid side effects
- Shorter steroid course may be just as effective for giant cell arteritis
- New Total-Body PET scanner could revolutionize vasculitis diagnosis
- New study links common arthritis treatments to diabetes risk
- New scan could spot hidden artery disease faster